<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03208192</url>
  </required_header>
  <id_info>
    <org_study_id>MCNC 01/2017</org_study_id>
    <nct_id>NCT03208192</nct_id>
  </id_info>
  <brief_title>Comparison of Hydro-dissection Versus Ultrasonic Aspirator in Division of Liver Parenchyma in Laparoscopic Resection</brief_title>
  <acronym>LLS</acronym>
  <official_title>Comparison of Hydro-dissection Versus Ultrasonic Aspirator in Division of Liver Parenchyma in Laparoscopic Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moscow Clinical Scientific Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Moscow Clinical Scientific Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: until now, there is no agreement about the safest and feasible method for liver
      parenchyma transection during laparoscopic liver resection.

      Study design: prospective, randomized, single-center The purpose of the study: comparison of
      short-term results of two methods of parenchyma liver transection during laparoscopic liver
      resection
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2017</start_date>
  <completion_date type="Anticipated">May 20, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>two groups will be compared. Group 1: liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon) and water-jet dissector (ERBEJET 2).
Group 2: liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon), and ultrasonic aspirator (Misonix/SonaStar Ultrasonic Surgical Aspiration System)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>1 day</time_frame>
    <description>absolute measurement of blood loss in relation to resection size (ml/cm2) Absolute blood loss will be calculated as the amount of blood (collected only during the parenchyma resection) in suction the container after the subtraction of all irrigating fluids and weighing operative sponges.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood loss relative to total blood volume (%)</measure>
    <time_frame>1 day</time_frame>
    <description>Patient-specific relative blood loss (RBL %) was calculated as follows:
RBL (%) = [intraoperative blood loss (mL) / estimated blood volume (mL)] x 100
Calculation of Total Blood Volume by Nadler's equation. The average blood volume is calculated as 75 ml/kg for men and 65 ml/kg for women, and in case of obesity 70 ml/kg for men and 60 ml/kg for women.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of liver parenchyma transaction</measure>
    <time_frame>1 day</time_frame>
    <description>Duration of liver parenchyma transaction (min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necessity to apply the Pringle maneuver.</measure>
    <time_frame>1 day</time_frame>
    <description>Necessity to apply the Pringle maneuver (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Pringle maneuver applications.</measure>
    <time_frame>1 day</time_frame>
    <description>Number of Pringle maneuver applications (data)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total duration of Pringle maneuver.</measure>
    <time_frame>1 day</time_frame>
    <description>The total duration of Pringle maneuver (min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the longest application of Pringle maneuver</measure>
    <time_frame>1 day</time_frame>
    <description>Duration of the longest application of Pringle maneuver (min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients needed for banked blood transfusion</measure>
    <time_frame>1 day</time_frame>
    <description>Number of patients needed for banked blood transfusion (data)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bank blood units needed for transfusion</measure>
    <time_frame>1 day</time_frame>
    <description>Number of bank blood units needed for transfusion (data)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of conversion to hybrid (with upper midline incision of 10 cm long), open or robotic surgery</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Rate of conversion to hybrid (with upper midline incision of 10 cm long), open or robotic surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open/lap surgery before laparoscopic procedure</measure>
    <time_frame>1 day</time_frame>
    <description>Open/lap surgery before laparoscopic procedure (yes/no)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>morbidity</measure>
    <time_frame>30 days</time_frame>
    <description>Morbidity according to Clavien-Dindo classification (it is advisable to activate complications class II-V)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Transection During Laparoscopic Liver Resection</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon) and water-jet dissector (ERBEJET 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon), and ultrasonic aspirator (Misonix/SonaStar Ultrasonic Surgical Aspiration System)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>liver transection during laparoscopic liver resection</intervention_name>
    <description>liver transection during laparoscopic liver resection</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with benign lesions (hemangioma, focal nodular hyperplasia [FNH],
             hepatocellular adenoma, biliary cystadenoma, hydatid echinococcosis [only with total
             pericystectomy]) and malignant tumors (colorectal cancer metastases in the liver
             [CRLM], hepatocellular carcinoma [HCC], intrahepatic cholangiocellular carcinoma,
             gallbladder cancer T1b-3NxMo without invasion into bile ducts and adjacent organs),
             which involves laparoscopic segmental or major resection of the liver.

          -  Gender: both, male and female

          -  Minimum age 18 years

          -  Maximum age: 80 years

          -  ASA physical status I-IV

          -  BMI up to 40 kg/m2

          -  No simultaneous extrahepatic intra-abdominal procedures (bile duct resection, colon
             resection, partial duodenum resection)

          -  Total bilirubin up to 100mmol/l if jaundice presents in non-cirrhotic patients

          -  If cirrhosis is present, class A and B according to CTP score

        Exclusion Criteria:

          -  â€¢ Difficulty index &gt; 12 points (see below)

               -  Tumor invasion of IVC or portal trunk (necessity of vascular reconstruction)

               -  Repeated liver resection before laparoscopic resection (the single resection
                  before is not a contraindication)

               -  Simultaneous extra-hepatic intra-abdominal procedures (bile duct resection, colon
                  resection etc.)

               -  Age under 18 years

               -  Age above 80 years

               -  ASA physical status &gt;IV

               -  BMI &gt; 40 kg/m2

               -  Total bilirubin &gt;100mmol/l if jaundice presents in non-cirrhotic patients

               -  If cirrhosis is present, class C according to CTP score

               -  Persons who are incapable of giving consent

               -  Pregnant or breast-feeding women

               -  Patients enlisted in other studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikhail Efanov, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Moscow Clinical Scientific Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikhail Efanov, MD, PhD</last_name>
    <phone>+7(916) 105-88-30</phone>
    <email>m.efanov@mknc.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ivan Kazakov, PhD</last_name>
    <phone>+79264740501</phone>
    <email>i.kazakov@mknc.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moscow Clinical scientific Center</name>
      <address>
        <city>Moscow</city>
        <state>Entuziastov shosse,86</state>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail Efanov, MD, PhD</last_name>
      <phone>+7(916) 105-88-30</phone>
      <email>m.efanov@mknc.ru</email>
    </contact>
    <contact_backup>
      <last_name>Ivan Kazakov, PhD</last_name>
      <phone>+79264740501</phone>
      <email>i.kazakov@mknc.ru</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2017</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Moscow Clinical Scientific Center</investigator_affiliation>
    <investigator_full_name>Ivan Kazakov</investigator_full_name>
    <investigator_title>Clinial Research</investigator_title>
  </responsible_party>
  <keyword>colorectal liver metastases</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>intrahepatic cholangiocellular carcinoma</keyword>
  <keyword>tumor of liver</keyword>
  <keyword>focal nodular hyperplasia liver</keyword>
  <keyword>hemangioma liver</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

